Otsuka eyes Sprycel synergies as it takes back Asian Busulfex rights
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical will regain all rights to its specialist oncology product IV Busulfex (busulfan) from current Asian licensee Kyowa Hakko Kirin when the two firms' contract expires at the end of March next year.